Janux officer sells 4,059 shares for tax withholding

Janux Therapeutics, Inc. reported that Chief Corp. & Business Development Officer Janeen Noel Doyle disposed of 4,059 shares of common stock on June 2, 2026 at a weighted average price of $14.029 per share.

Rhea-AI Filing Summary

Janux Therapeutics, Inc. reported that Chief Corp. & Business Development Officer Janeen Noel Doyle disposed of 4,059 shares of common stock on June 2, 2026 at a weighted average price of $14.029 per share. According to the footnotes, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units, indicating a routine, non-discretionary transaction rather than an active portfolio decision. Following this sale, Doyle directly holds 75,941 shares of Janux Therapeutics common stock.

Insider Trade Summary

Net Seller: 4,059 shares

Net Sell 1 txn

Insider Doyle Janeen Noel

Role Chief Corp. & Bus. Dev. Ofcr

Sold 4,059 shs ($57K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,059	$14.029	$57K

Holdings After Transaction: Common Stock — 75,941 shares (Direct)

Footnotes (2)

1. F1. The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 4,059 shares Weighted average sale price: $14.029 per share Post-transaction holdings: 75,941 shares +1 more

4 metrics

Shares sold 4,059 shares Common stock automatically sold on June 2, 2026

Weighted average sale price $14.029 per share Open-market sale to cover tax withholding

Post-transaction holdings 75,941 shares Directly owned common stock after sale

Sale price range $13.96–$14.03 per share Range of individual sale prices within reported transaction

Key Terms

restricted stock units, tax withholding obligations, weighted average sale price, open-market sale

4 terms

restricted stock units financial

"associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"automatically sold to cover tax withholding obligations"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $14.029"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did JANX executive Janeen Noel Doyle report?

Janeen Noel Doyle reported selling 4,059 shares of Janux Therapeutics common stock. The shares were automatically sold on June 2, 2026 to cover tax withholding obligations associated with the vesting of restricted stock units, rather than as a discretionary open-market sale.

At what price were the JANX shares sold in Janeen Noel Doyle’s Form 4?

The reported weighted average sale price was $14.029 per share. Footnotes state the sale prices ranged between $13.96 and $14.03, and detailed price breakdowns are available upon request from the company, the SEC staff, or any Janux security holder.

How many JANX shares does Janeen Noel Doyle own after this reported sale?

After the transaction, Janeen Noel Doyle directly holds 75,941 shares of Janux Therapeutics common stock. This context shows that the 4,059 shares sold to cover tax withholding represent a relatively small portion of her overall direct equity position in the company.

Was the JANX insider sale by Janeen Noel Doyle a discretionary trade?

The filing states the shares were automatically sold to cover tax withholding obligations from restricted stock unit vesting. This indicates a routine, mechanistic disposition tied to compensation, not a discretionary decision to reduce exposure in Janux Therapeutics stock.

What does it mean that JANX shares were sold to cover tax withholding?

Selling shares to cover tax withholding means part of an equity award is sold to pay income taxes due at vesting. For Janux, Doyle’s 4,059 shares were sold automatically for this purpose, converting a portion of her vested restricted stock units into cash to satisfy tax liabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Janeen Noel

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp. & Bus. Dev. Ofcr

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S(1)		4,059	D	$14.029(2)	75,941	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $14.029 and the range of prices were between $13.96 and $14.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ James Pennington, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)